Ying Yan

Associate Professor


Dr. Ying Yan was born in Dali, Yunnan Province, China. She completed her B.Sc. from Yunnan University, Kunming, China and then received her Ph.D.(Cell Biology) from Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. She then pursued her Postdoc (Molecular Biology) from Department of Cell Biology and Neuroscience, University of Texas Southwestern Medical Center at Dallas and Postdoc (Biochemistry & Pharmacology) from Department of Pharmacology, University of Texas Southwestern Medical Center at Dallas, TX. She has attended various seminars. She has many publications. Presently she is an Associate Professor in the Department of Biochemistry & Molecular Biology at College of Medicine, University of Nebraska Medical Center, United States.


Area of Interest

My research interest include: (1) signaling mechanisms that regulate the response of cancer cells to therapeutics and their contributions to therapy resistance;

(2) molecular mechanisms of tumorigenesis.

My current research focuses on two areas: (i) Rac1 signaling in chemo/radio resistance of cancer cells and (ii) protein serine/threonine phosphatase 2A in tumorigenesis of pancreatic cancer.

top publication

1. Arnst JL, Hein AL, Palermo N, Natarajan A &Yan Y. Characterization of novel chemical inhibitors of Rac1 GTPase. In preparation
2. Lakamp-Hawley AS, Yan Y, Borgstahl GEO & Ouellette MM. The Human CST complex contains two separate ssDNA binding pockets possessing different binding properties. In preparation
3. Burchett KM, Yan Y& Ouellette MM. Inhibitors of telomerase and poly(ADP-ribose)polymerases synergize to limit the lifespan of pancreatic cancer cells. Manuscript in preparation.
4. Hein AL, Post CM, Sheinin YM, Lakshmanan I, Natarajan A, Enke CA, Batra SK, Ouellette MM &Yan Y. RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment.Oncogene, in press, 2016
5. Hein AL, Seshacharyulu P, Rachagani S, Sheinin YM, Ponnusamy MP, Mumby MC, Ouellette MM, Batra SK &Yan Y. PR55α subunit of protein phosphatase 2A supports the tumorigenic and metastatic potential of pancreatic cancer cells by sustaining hyperactive oncogenic signaling, Cancer Research, DOI: 10.1158/0008-5472, published Online First on Feb 18, 2016
6. Yan Y& Ouellette MM. Rac1 GTPase in pancreatic cancer. Aging, 7(9): 609–610, 2015
7. Lakshmanan I., Seshacharyulu P., Haridas D., Rachagani S., Gupta S., Joshi S., Guda C., Yan Y, Jain M, Ganti AK, Ponnusamy MP & Batra SK.Novel HER3/MUC4 oncogenic signaling exacerbates the tumorigenic phenotypes of pancreatic cancer cells. Oncotarget6(25):21085-99. PMID: 26035354, 2015
8. Choi KH, Lakamp-Hawley AS, Kolar C, Yan Y, Borgstahl GEO& Ouellette MM. The Oligonucleotide/Oligosaccharide Binding fold 1 (OB1) of human POT1 recognizes both telomeric and nontelomeric DNA motifs. Biochimie, 115:17–27, PMC4500675, 2015
9. SeshacharyuluP, Ponnusamy MP, Rachagani S, Lakshmanan I, Haridas D, Yan Y, Ganti AK & Batra SK. Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. Oncotarget,6(7):5164-81, PMC4467140, 2015
10. Yan Y, Hein A, Greer PM, Wang Z, Kolb RH, Batra SK & Cowan KH. A novel function of HER2/Neu in the activation of G2/M checkpoint in response to -irradiation. Oncogene, 9 34(17):2215-26. PMC4362969, 2015
11. Yan Y, Hein A, Etekpo A, Burchett KM, Lin C, Enke CA, Batra SK, Cowan KH & Ouellette MM.Inhibition of RAC1 GTPase sensitizes pancreatic cancer to γ-irradiation.Oncotarget, 5(21):10251-70, PMC4279370, 2014
12. Hein LA, Ouellette MM &Yan Y. Radiation-induced signaling pathways that promote cancer cell survival.International Journal of Oncology,45: 1813-1819, 2014
13. Burchett KM, Yan Y& Ouellette MM. Telomerase inhibitor imetelstat (GRN163L) limits the lifespan of pancreatic cancer cells. PLoS One, 9(1): e85155,PMCID: PMC3883701, 2014
14. Peters HL, Yan Y& Solheim JC. APLP2 regulation of the expression of MHC class I molecules on irradiated Ewing’s sarcoma cells. OncoImmunology, 2(10): e26293. PMC3862638, 2013
15. Peters HL, Yan Y, Nordgren TM, Cutucache CE, Joshi SS & Solheim JC. Amyloid precursor-like protein 2 reduces Ewing sarcoma cell radiosensitivity and is elevated in immune-evasive Ewing sarcoma cells. Cancer Biology & Therapy, 14:8, 752–760. PMID: 23792571, 2013
16. PandeyP, SeshacharyuluP, DasS, RachaganiS, PonnusamyMP, Yan Y, JohanssonSL, DattaK, LinMF & Batra SK.Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway. Br J Cancer, 1–11 | doi: 10.1038/bjc.2013.160. PMID: 23598299, 2013
17. Kolb RH, Greer PM, Cao PT, Cowan KH&Yan Y. ERK1/2 signaling plays an important role in topoisomerase II poison-induced G2/M checkpoint activation. PLoS One, 7(11):1-16.PMID: 23166842, 2012
18. Pessetto ZY, Yan Y, Bessho T &Natarajan A. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of Olaparib in breast cancer cells: A proof of concept study for synthetic lethal therapeutic option. Breast Cancer Res Treat, 134(2):511-517. PMID: 22562176, 2012
19. Yan Y, Greer PM, Cao PT, Kolb RH &Cowan KH. RAC1 GTPase plays an important role in -irradiation induced G2/M checkpoint activation. Breast Cancer Research, 14(2):R60. PMID: 22494620, 2012
20. Golla RM,Li M, Shen Y,Ji M,Yan Y,Fu K,Greiner TC,McKeithan TW&Chan WC. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxiatelangiectasiamutated (ATM) on the chemosensitivity of mantlecelllymphoma to agents that induceDNAstrandbreaks. HematolOncol,30(4):175-9. PMID: 22170260. No PMCID, 2011
21. Yan Y, Cao PT, Nagengast ES, Kolb RH, Black CP, Mumby MC & Cowan KH. Phosphatase 2A plays an essential role in -irradiation-induced G2/M checkpoint response. Oncogene, 29:4317-4329. PMID: 20498628, 2010
22. Yan Y, Black CP, Cao PT, Kolb RH, Haferbier JL, Ristow AM & Cowan, KH. -Irradiation-induced DNA-damage checkpoint activation involves feedback regulation between extracellular signal-regulated kinase 1/2 and BRCA1. Cancer Res, 68:5113-5121. PMID: 18593910, 2008